308 related articles for article (PubMed ID: 16051956)
1. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer.
Mann GB; Fahey VD; Feleppa F; Buchanan MR
J Clin Oncol; 2005 Aug; 23(22):5148-54. PubMed ID: 16051956
[TBL] [Abstract][Full Text] [Related]
2. Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer.
Sutela A; Vanninen R; Sudah M; Berg M; Kiviniemi V; Rummukainen J; Kataja V; Kärjä V
Acta Oncol; 2008; 47(1):38-46. PubMed ID: 17851859
[TBL] [Abstract][Full Text] [Related]
3. The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer.
Park SY; Kim KS; Lee TG; Park SS; Kim SM; Han W; Noh DY; Kim SW
Am J Surg; 2009 Feb; 197(2):266-9. PubMed ID: 18614146
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
5. A comparison of immunohistochemical staining for oestrogen receptor, progesterone receptor and HER-2 in breast core biopsies and subsequent excisions.
Wood B; Junckerstorff R; Sterrett G; Frost F; Harvey J; Robbins P
Pathology; 2007 Aug; 39(4):391-5. PubMed ID: 17676479
[TBL] [Abstract][Full Text] [Related]
6. Preoperative profiling of symptomatic breast cancer by diagnostic core biopsy.
Cahill RA; Walsh D; Landers RJ; Watson RG
Ann Surg Oncol; 2006 Jan; 13(1):45-51. PubMed ID: 16378157
[TBL] [Abstract][Full Text] [Related]
7. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information.
Biesterfeld S; Schröder W; Steinhagen G; Koch R; Veuskens U; Schmitz FJ; Handt S; Böcking A
Anticancer Res; 1997; 17(6D):4723-9. PubMed ID: 9494596
[TBL] [Abstract][Full Text] [Related]
9. Prognostic implications of HER-2 status in steroid receptor-positive, lymph node-negative breast carcinoma.
Peiró G; Adrover E; Aranda FI; Peiró FM; Niveiro M; Sánchez-Payá J
Am J Clin Pathol; 2007 May; 127(5):780-6. PubMed ID: 17439837
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
[TBL] [Abstract][Full Text] [Related]
11. Biopathologic profile of breast cancer core biopsy: is it always a valid method?
Cavaliere A; Sidoni A; Scheibel M; Bellezza G; Brachelente G; Vitali R; Bucciarelli E
Cancer Lett; 2005 Jan; 218(1):117-21. PubMed ID: 15639347
[TBL] [Abstract][Full Text] [Related]
12. Breast hormonal receptors test should be repeated on excisional biopsy after negative core needle biopsy.
Khoury T; Zakharia Y; Tan W; Kulkarni S; Liu W; Zhang S; Wilding GE; Edge S
Breast J; 2011; 17(2):180-6. PubMed ID: 21306471
[TBL] [Abstract][Full Text] [Related]
13. Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens?
Burge CN; Chang HR; Apple SK
Breast; 2006 Apr; 15(2):167-72. PubMed ID: 16095904
[TBL] [Abstract][Full Text] [Related]
14. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
15. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
[TBL] [Abstract][Full Text] [Related]
16. Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast.
Boland GP; McKeown A; Chan KC; Prasad R; Knox WF; Bundred NJ
Br J Cancer; 2003 Jul; 89(2):277-83. PubMed ID: 12865917
[TBL] [Abstract][Full Text] [Related]
17. Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related.
Huang HJ; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Christiaens MR; Vergote I
Breast Cancer Res Treat; 2005 May; 91(1):81-7. PubMed ID: 15868434
[TBL] [Abstract][Full Text] [Related]
18. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E
Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
[TBL] [Abstract][Full Text] [Related]
19. Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer.
Neven P; Van Calster B; Van den Bempt I; Van Huffel S; Van Belle V; Hendrickx W; Decock J; Wildiers H; Paridaens R; Amant F; Leunen K; Berteloot P; Timmerman D; Van Limbergen E; Weltens C; Van den Bogaert W; Smeets A; Vergote I; Christiaens MR; Drijkoningen M
Breast Cancer Res Treat; 2008 Jul; 110(1):153-9. PubMed ID: 17687649
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
